#### **ASSESSING IMPACT OF STEWARDSHIP: THE WHY, WHEN, AND HOW OF INTERRUPTED TIME SERIES**

Jessina C. McGregor, PhD College of Pharmacy Oregon State University Oregon Health & Science University mcgregoj@ohsu.edu



#### COI & DISCLOSURES

- Contracted research
  - Merck
- Investigator initiated research
  - AHRQ, CDC, Merck
- Other support
  - PCORI



#### LEARNING OBJECTIVES

- 1. Define the importance of rigorous evaluation of antimicrobial stewardship interventions
- 2. Identify what research/quality improvement questions are best answered through interrupted time series
- 3. Identify different outcome types useful in evaluating stewardship efforts
- 4. Identify design elements that allow for development of a strong ITS study
- 5. Review fundamentals of statistical analysis for interrupted time series



# WHY EVALUATE ASP INTERVENTIONS?

• Demonstrate intervention effect

- Defined, measurable outcome
- "Prove" effect was due to demonstration
  - Rule out alternate explanations



#### "RIGOROUS" EVALUATION OF ASP

# • Why "rigorous"?

- Minimize bias and error
- Maximize causal inference
- Support identification of best practice
  Maximal impact on patient care



# WHAT IS ITS?

- A type of quasi-experimental study
  - <u>Not</u> observational or ecological
- Non-randomized, interventional
- Before and after studies
  - Multiple regularly spaced measurements before and after intervention
- Evaluate effect of an intervention implemented at group level
  - Antibiotic time out
  - Restriction policy
- Can include different design elements
  - With/without control groups
  - Staggered roll out



• What is your research question?

Group/population level effect

 Reduction in antibiotic use
 Reduction in MDRO rates
 Reduce C. difficile infection



# • Population/patient setting characteristics

- Consistent across time
- Defined and enumerable
- At-risk population



• Intervention characteristics

- Group-level intervention
- Not randomly assigned
- Clear implementation date is known
- Uniformly applied
- Examples
  - •New antibiotic restriction policy
  - •Antibiotic time out
  - Provider education



• Outcome characteristics

- Group/system level outcome
- Measurable across units of time
- Examples
  - Cost
  - Antibiotic orders
  - Infection/Colonization
  - Resistance




#### **DESIGNING RIGOROUS ITS STUDIES**


# INTERRUPTED TIME SERIES $O_1 O_2 O_3 O_4 O_5$ $\int O_6 O_7 O_8 O_9 O_{10}$ time

#### • Example: Evaluation of antibiotic time out policy

- Setting: Acute care hospital
- Intervention: EHR alert to review systemic antibiotics after 72 hours
- Outcome: CDI rate







#### Advanced Design Features


• Increase complexity of design framework

- If pattern of outcome measurements over time conforms to the increasingly complex pattern, more evidence for causal inference
- Increasingly unlikely that outside influencing factors, bias, confounders could have resulted in the observed pattern



#### DESIGNS WITH CONTROL GROUPS

# Either of these designs could also be improved by adding a control...




#### DESIGNS WITH CONTROLS

- Control group selection
  - Affected by same external influences
  - Outcome in control group not affected by intervention implementation in "treatment" group
- "Control" variables
  - A.K.A.=Nonequivalent dependent variables
  - Alternate "outcome" variable that you expect not to change as a result of intervention
    - Example: hypoglycemia




#### STAGED ROLL OUT OF INTERVENTION

AKA Stepped wedge design




#### STAGED ROLL OUT OF INTERVENTION

AKA Stepped wedge design



**College of Pharmacy** 

#### **REMOVED INTERVENTION**





#### STRENGTHS OF ITS DESIGN

- Evidence against pre-existing trends and regression to the mean
- Demonstrates immediate and sustained effects
- Easy to visualize intervention effect
- Multiple outcomes can be assessed
  - Process measures, patient outcomes



#### WEAKNESS OF ITS DESIGN

- Often requires longer periods of baseline and follow-up data
  - Particularly for rare outcomes and small populations
- Changes over time can introduce bias
- Validity of outcome measurements may change over time



#### **STATISTICAL ANALYSIS FOR ITS**

#### INTERRUPTED TIME SERIES

- Most powerful sub-group of quasi-studies
- Can detect immediate effects of intervention
  - Change in intercept
- Can detect long-term effects of interventions
  - Change in slope/trend

Segmented Regression



#### ANALYZING ITS STUDIES

# • Want to retain advantages of ITS study design

- <u>Generally 10-20 recommended for analysis</u>
  - 3 observations each, before and after intervention is absolute minimum to be called ITS
- Regularly spaced time intervals
- Need to account for correlation and secular trends



# ANALYZING ITS

- Why can't we summarize the pre-intervention and post-intervention data and compare (i.e., compare two means)?
  - Reduces the study to a single pretest-postest design
  - Intervention effects can be over- or under-estimated






Figure 3. An example of an interrupted time series in which the effect of the interventions is overestimated by analysis of mean data before and after the intervention.<sup>10</sup>



Ramsay et al. JAC (2003) 52: 764-771




Figure 4. An example of an interrupted time series in which the effect of the interventions is underestimated by analysis of mean data before and after the intervention.<sup>33</sup>



Ramsay et al. JAC (2003) 52: 764-771

# ANALYZING ITS

- Why can't we use our 'standard' regression models?
  - Need to model change in mean outcome and change in trend in outcome
  - Data are not independent--correlated
- What if we use 'standard' regression models anyway?
  - Parameter estimates are not biased
  - SD of parameter estimates are biased
    - Biased statistical test
    - Generally, interventions effects will appear statistically significant when they are not



#### ARIMA MODELS

#### • Auto Regressive Integrated Moving Average

- Analyzes and forecasts equally spaced univariate time series data, including intervention or ITS data
- Models both parameters of interest and correlation structure

• Account for variability over time, seasonal trends, etc.



#### ARIMA MODELS

#### • ARIMA Family (SAS: PROC ARIMA)

- Includes subsets that include
  - ARMA: auto regressive and moving average
  - Autoregressive
    - SAS PROC ARIMA
    - PROC AUTOREG
- <u>Highly</u> recommend working with a statistician
  - Modeling process is complex
  - To follow is an overview



### ARIMA MODELS

#### • Model Components


- Deterministic
  - Parameters of our time series
- Stochastic ("noise" component)
  - Unsystematic
    - Random "shocks"
  - Systematic
    - Responsible for autocorrelation
    - Major goal is to identify/model structure
      - Leaves only unsystematic portion
      - Can then calculate unbiased estimates of SD



# ANALYZING ITS

- How do we model the deterministic component? (i.e., how do we set up our model parameters?)
- Segmented Regression
  - Model parameters are entered in such a fashion that allows for changes in mean outcome levels (intercepts) and trends in outcome (slopes)
  - Can be used with various statistical models (not limited to ARIMA)





**College of Pharmacy** 

#### SEGMENTED REGRESSION FOR ITS

 $Y_t = \beta_0 + \beta_1(time_t) + \beta_2(intervention_t) + \beta_3(time after intervention_t) + e_t$ 

Time	Continuous variable; time since study start
Intervention	0 = Pre-intervention period 1 = Post-intervention period
Time after Intervention	Continuous variable; time since intervention




#### SEGMENTED REGRESSION FOR ITS

 $Y_t = \beta_0 + \beta_1(time_t) + \beta_2(intervention_t) + \beta_3(time after intervention_t) + e_t$ **Pre-Intervention Slope Post-Intervention Change in Slope Post-Intervention Change in Pre-Intervention Intercept** Intercept У Х

**College of Pharmacy** 

### SEGMENTED REGRESSION FOR ITS

 $Y_t = \beta_0 + \beta_1(time_t) + \beta_2(intervention_t)$ 



**Figure 2.** Interrupted time-series data regarding length of hospital stay (LOS) simulated from a segmented linear regression model with a change in slope (before vs. after the intervention), fit with a nonsegmented linear regression model that cannot estimate a change in slope (*A*) and a segmented linear regression model that can estimate a change in slope (*B*). The intervention was implemented at month 36.



Shardell et al. Clin Infect Dis 2007


+  $e_{\rm t}$ 

# ARIMA MODELS

### • Model Components

- Deterministic
  - Parameters of our time series
- Stochastic ("noise" component)
  - Unsystematic
    - Random "shocks"
  - Systematic
    - Responsible for autocorrelation
    - Major goal is to identify/model structure
      - Leaves only unsystematic portion
      - Can then calculate unbiased estimates of SD





**College of Pharmacy** 

## ARIMA MODELS

- How do we model the structure of the stochastic systematic component? (i.e., the autocorrelation structure)
  - Three types of functions; user-defined
    - Autoregressive
      - Past observations can be used to predict the current observation
    - Differencing
      - E.g., subtraction of one observation from the previous observation
      - Helps to make the data "independent" of time
        - Required for ARIMA
    - Moving Average
      - Aka running average or rolling average
      - Used to smooth out short-term fluctuations and identify longer-term trends



## BUILDING ARIMA MODELS

- I. Model the correlation structure (stochastic or noise component)
  - 1. Identification stage
    - Defines the autoregressive, differencing, and moving average functions
  - 2. Estimation stage
    - Estimate model parameters
  - 3. Diagnostic stage
    - Generate diagnostic statistics to judge model fit
  - 4. If diagnostics indicate inadequate model, repeat steps 1-2
- II. Model and test the intervention (the deterministic component; segmented regression)
  - Level of complexity dependent on the study design and the nature of expected effect of the intervention



## NOTES ON ARIMA MODELING

- For outcome data that are approximately normally distributed
- Count data
  - Rates
    - Approximately normally distributed if based on large numbers
  - Generalized ARMA models
    - E.g. Poisson regression
    - Available in R
- Models can be made more complex
  - Control groups
  - Account for lagged intervention effects
  - Etc....



### **PRACTICAL TIPS FOR CONDUCTING AN ITS STUDY**

• What is the intervention

- Does it contain multiple components?
- Does fidelity vary over time?
- Is a lagged effect anticipated?



- Define study population
- Evaluate baseline data
  - How far back can you collect baseline data?
    - Consider other policies, interventions, institutional changes
    - Longer pre-intervention period is preferrable
- Expected impact
  - Appropriate <u>unit</u> of time
  - Appropriate duration of study



- Consider other influences on outcome
  - Drug shortages, seasonality, etc.
- If possible study multiple outcomes
  - Often difficult to identify change in event rates of interest in our field
  - Increase likelihood of documenting interventional impact
    - Process/intermediate measures



## CONDUCTING ITS STUDIES

### • Can incorporate higher-level design features

- Control group
- Removed treatment
- Staged roll out



### • Data collection

- Be systematic
  - Need equally space time intervals
- Collect descriptive data—establish generalizability
- Consider other mitigating factors
  - Outbreaks
  - Changes in formulary, drug shortages, etc.
- Enumerate your denominator
  - Average number of antibiotics ordered per <u>patient</u>
  - Percent <u>of patients</u> treated according to guidelines
  - Average quantity of alcohol-based hand rub used in <u>a unit</u> (consider # HCWs)



#### • Data management

- Data structure
  - Plan ahead
- Consider granularity
  - Ability to collapse data into different time units
  - Ability to stratify outcome data (e.g., antibiotics)



### • Data analysis

- Make a plan *a priori*
- Intervention
  - Date(s)
  - Phases?
  - Staggered roll out?
- Number observations before/after intervention
- Graphical representations of data are useful
  Plotting the average/predicted effects



# ITS SUMMARY

- Useful for studying system/group level effects of intervention
  - Immediate and gradual effects assessed through segmented regression
- Analysis methods require adjustment for correlation structure
- Advanced design features strengthen ability to make causal inference
- Design and implementation requires some planning
  - Most difficult aspect is planning study duration



### **REFERENCES & RESOURCES**

### <u>Useful Background on ITS:</u>

- Cook TD and Campbell DT (1979). <u>Quasi-experimentation :</u> <u>design & analysis issues for field settings</u>. Chicago, Rand McNally College Pub. Co. (This first edition contains more information on analysis than the second edition below)
- Shadish WR, Cook TD and Campbell DT (2001). <u>Experimental</u> <u>and quasi-experimental designs for generalized causal inference</u>. Boston, Houghton Mifflin.
- Schweizer ML, Braun BL, Milstone AM. "Research Methods in Healthcare Epidemiology and Antimicrobial Stewardship—Quasi-Experimental Designs. Infect Control Hosp Epidemiol 37(10): 1135-40.
- Harris AD, Lautenbach E and Perencevich E (2005). "A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance." <u>Clin Infect</u> <u>Dis</u> 41(1): 77-82.
- Wagner AK, Soumerai SB, Zhang F and Ross-Degnan D (2002). "Segmented regression analysis of interrupted time series studies in medication use research." <u>J Clin Pharm Ther</u> 27(4): 299-309.



### **REFERENCES & RESOURCES**

#### <u>Intermediate/Advanced References to assist with</u> <u>design and analysis:</u>

- Shardell M, Harris AD, El-Kamary SS, Furuno JP, Miller RR and Perencevich EN (2007). "Statistical analysis and application of quasi experiments to antimicrobial resistance intervention studies." <u>Clin Infect</u> <u>Dis</u> 45(7): 901-7.
- McDowall D, McCleary R, Meidinger EE and Hay Jr. RA (1980). <u>Interrupted Time Series Analysis.</u> Beverly Hills, Calif., Sage Publications.
- Ramsay C, Brown E, Hartman G and Davey P (2003). "Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing." <u>J Antimicrob Chemother</u> 52(5): 764-71.
- Harbarth S and Samore MH (2008). "Interventions to control MRSA: high time for time-series analysis?" <u>J Antimicrob Chemother 62(3): 431-3.</u>
- Zhang F, Wagner AK, Ross-Degnan D. Simulation-based power calculation for designing interrupted time series analyses of health policy interventions. J Clin Epidemiol. Nov 2011;64(11):1252-1261.
- McLeod AI, Vingilis ER. Power computations in time series analyses for traffic safety interventions. Accid Anal Prev. May 2008;40(3):1244-1248.



### **REFERENCES & RESOURCES**

#### ITS Examples in the literature:

- 1. Taggart LR et al. "Differential outcome of an antimicrobial stewardship audit and feedback program in two intensive care units: a controlled interrupted time series study." BMC Infect Dis. 2015 Oct 29;15:480.
  - Controlled ITS, with non-dependent outcome
- 2. Standiford et al. "Antimicrobial Stewardship at a Large Tertiary Care Academic Medical Center: Cost Analysis Before, During, and After a 7-Year Program." Infect Control Hosp Epidemiol. 2012 Apr 33 (4): 338-45.

• ITS with removed intervention

3. Elligsen et al. "Audit and Feedback to Reduce Broad-Spectrum Antibiotic Use among Intensive Care Unit Patients A Controlled Interrupted Time Series Analysis." Infect Control Hosp Epidemiol. 2012 Apr 33 (4): 354-61.

• ITS with control

4. Palmay et al. "Hospital-wide Rollout of Antimicrobial Stewardship: A Stepped-Wedge Randomized Trial." Clin Infect Dis. 59(6): 867-874.

• Staged-roll out of intervention

